Provider intervention associated with usage decline of high risk meds

Intervention designed to impact use of high-risk medications evaluated as part of CMS Star metric

Prime sent letters to doctors to let them know they had prescribed high-risk medications to Medicare members. The intervention group’s high-risk medication percentage declined more than the control group. It was a statistically significant difference. Certain medications carry a greater risk of adverse events for the older adults than for younger people. Safer options exist for many high-risk medications.

Impact of First Fill Intervention on High-risk Medication Usage in a One Million Member Medicare Population (Fall 2016)

About Prime Therapeutics

Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization serving health plans, employers and government programs. Prime is collectively owned by 19 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. Magellan Rx Management, a Prime Therapeutics LLC Company, is a pioneer in specialty and medical drug management and a leader in serving public sector state government programs. Together Prime and Magellan Rx provide a wide range of clients with solutions that bridge the distance between medical and pharmacy management. For more information visit www.primetherapeutics.com and www.magellanrx.com, or follow us on Twitter at @Prime_PBM and @Magellan_Rx.

Provider intervention associated with usage decline of high risk meds

Intervention designed to impact use of high-risk medications evaluated as part of CMS Star metric

Impact of First Fill Intervention on High-risk Medication Usage in a One Million Member Medicare Population (Fall 2016)

About Prime Therapeutics

Related news

Specialty Drug Pipeline Quarterly Update: September 2023

Traditional Drug Pipeline Quarterly Update: September 2023

Gene/Cell Therapy Quarterly Update: September 2023